Partial
Partially Aligned
Patient Risk:
Low
Summary
Several general statements about sucralfate’s active ingredient and available dosage forms are consistent with the provided label excerpts, but many claims about FDA generics substitution rules, pharmacy substitution practices, and specific confirmation steps (expiration/lot tracking) are not supported by the supplied prescribing information and are therefore unsupported.
Category Scores
Accurate Statements
Sucralfate is the active ingredient in brand-name products used to help protect the lining of the stomach and/or duodenum.
Label describes local action and ulcer healing of duodenal ulcer (Section 12/14); however the specific wording about “protect the lining of the stomach and/or duodenum” is only partially reflected. Support is strongest for duodenal ulcer local protective/adherent complex mechanism (Sections 12, 14).
Sucralfate generic products may be sold as tablets.
Not demonstrated in the provided label: “Equivalence of sucralfate oral suspension to sucralfate tablets has not been demonstrated” (Section 14). This indicates tablets exist as a formulation class, but tablet-specific equivalence is not shown.
Sucralfate generic products may be sold as suspension (liquid).
This specific label is for sucralfate oral suspension and includes its composition and dosing form (Sections DESCRIPTION, 2).
To confirm a sucralfate product, one should check the active ingredient: “sucralfate.”
Label identifies active ingredient as sucralfate (DESCRIPTION).
To confirm a sucralfate product, one should check the dosage form (tablet vs suspension).
The provided label is for oral suspension; it also discusses non-equivalence to tablets (Section 14).
Unsupported Statements
In the US, an approved generic sucralfate product should have the same active ingredient (sucralfate) and generally the same strength and dosage form as the reference brand.
Not supported by the supplied prescribing information excerpts (FDA generic substitution/AB-rated requirements are not addressed in the provided label text).
Practical differences patients may notice between brand-name sucralfate and generic sucralfate can come from non-active ingredients and the specific formulation (tablet vs suspension).
Not supported by the provided prescribing information excerpts; label does not discuss excipient-driven patient-noticeable differences between brand and generic.
Pharmacies substitute a generic product only within the same dosage form and strength unless the prescription specifies otherwise.
Not supported by the provided prescribing information excerpts; pharmacy substitution practices are not described.
If a prescription label says “sucralfate” without “dispense as written” (DAW), pharmacies typically can dispense a generic equivalent.
Not supported by the provided prescribing information excerpts; DAW/substitution rules are not discussed.
If a prescription specifies a brand or DAW, substitution may not be allowed.
Not supported by the provided prescribing information excerpts.
To confirm a sucralfate product, one should check the strength (mg or g per dose).
The label includes a specific dose/strength for the provided formulation (1 gram/10 mL) (Section 2, DESCRIPTION), but the claim that patients “should check” strength as a general confirmation step is not supported as guidance in the provided label excerpts.
To confirm a sucralfate product, one should check the directions (times per day and whether to take on an empty stomach).
The label provides dosing directions (Section 2) but does not provide patient instruction framed as a confirmation/checklist step.
To confirm a sucralfate product, one should check expiration and manufacturer lot information for tracking.
The provided prescribing information excerpts do not include instructions to check expiration/lot for confirmation or tracking.
Sucralfate is an older drug.
Not supported by the provided prescribing information excerpts.
Many generic manufacturers exist for sucralfate.
Not supported by the provided prescribing information excerpts.
Contradictions
Important Omissions
Label-relevant administration warning that sucralfate oral suspension must be administered only by the oral route and not intravenously.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most statements are about identification/substitution and existence of formulations, with limited direct safety impact. However, omission of the label’s key warning about route of administration reduces safety completeness.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims about US generic substitution/DAW pharmacy practices and general patient confirmation/handling steps are not supported by the provided prescribing information excerpts.
Suggested Improvement
Limit claims to content explicitly supported by the supplied label (e.g., active ingredient, that this labeled product is oral suspension, and label dosing/administration and warnings). Remove or qualify statements about generic approval expectations, pharmacy substitution rules, and expiration/lot checking unless supported by the provided label text.